Gilead Sciences | GILD - Ebit

Stock Price
143.28
Daily Change
0.39 0.27%
Monthly
21.12%
Yearly
46.22%
Q1 Forecast
137.58

Gilead Sciences reported $3.51B in EBIT for its fiscal quarter ending in September of 2025.





Ebit Change Date
AbbVie USD 5.72B 69M Jun/2025
Agios Pharmaceuticals USD -116.87M 10.19M Sep/2025
ALKERMES USD 89.08M 3.9M Sep/2025
Alnylam Pharmaceuticals USD -29.96M 34.85M Sep/2025
Amgen USD 3.96B 464M Dec/2025
Biogen USD 659.6M 157M Sep/2025
BioMarin Pharmaceutical USD -31.69M 308.58M Sep/2025
Bristol-Myers Squibb USD 4.04B 1.78B Sep/2025
Eli Lilly USD 7.02B 3.32B Jun/2025
Gilead Sciences USD 3.51B 810M Sep/2025
GlaxoSmithKline GBP 2.79B 716M Sep/2025
Glaxosmithkline GBP 3.76B 1.69B Sep/2025
Incyte USD 431.31M 120.49M Sep/2025
J&J USD 5.11B 2.3B Dec/2025
Merck USD 6.24B 1.32B Dec/2025
Moderna USD -260M 557M Sep/2025
Neurocrine Biosciences USD 239.3M 93.7M Sep/2025
Novartis USD -9.19B 13.87B Jun/2025
Pfizer USD 4.65B 71M Dec/2025
PTC Therapeutics USD 3.49M 38.35M Sep/2025
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Sanofi EUR 1.7B 2.17B Dec/2025
Sarepta Therapeutics USD -62.88M 178.46M Sep/2025
United Therapeutics USD 389.3M 112.4M Sep/2025
Vertex Pharmaceuticals USD 1.24B 84.6M Sep/2025